Increasing trend of diabetes combined with hypertension or hypercholesterolemia: NHANES data analysis 1999-2012

Yongfeng Song, Xiaoyun Liu, Xiaolin Zhu, Bin Zhao, Bo Hu, Xia Sheng, Lan Chen, Miao Yu, Tao Yang, Jiajun Zhao, Yongfeng Song, Xiaoyun Liu, Xiaolin Zhu, Bin Zhao, Bo Hu, Xia Sheng, Lan Chen, Miao Yu, Tao Yang, Jiajun Zhao

Abstract

In order to prevent cardiovascular endpoints, control of diabetes, hypertension and hypercholesterolemia is a necessity as those risk factors frequently occur in combination. Prevalence trends of concurrent diabetes, hypertension and hypercholesterolemia in 36,673 subjects were obtained from the National Health and Nutrition Examination Survey (NHANES) from 1999-2012. The prevalence of concurrent diabetes, hypertension and hypercholesterolemia increased from 3% in 1999-2000 to 6.3% in 2011-2012 (P < 0.001). The diabetes with concurrent hypertension or hypercholesterolemia incidences also increased significantly, while the occurrence of concurrent hypertension and hypercholesterolemia was stable over the study period. Overall medical drug treatments for concurrent diabetes, hypertension, hypercholesterolemia were improved from 69.8% in 1999-2006, to 82.4% in 2007-2012 (P = 0.002). Treatment cost coverage rates in any combinations with diabetes were 79-82.4% and 90.7% in the subgroup of concurrent hypertension and hypercholesterolemia. General treatment goal achievement rates were <25%, the lowest rate being 14.2% in the subject groups with three combined risk factors. The treatment goal achievement rates in two subgroups with concurrent diabetes were 20.1% (with hypertension) and 17% (with hypercholesterolemia) and 24.5% in the group without diabetes. Cost coverage improved in all combinations, but the general treatment goal achievement rates were low, especially in the groups with concurrent diabetes.

Figures

Figure 1. Number of NHANES participants by…
Figure 1. Number of NHANES participants by survey cycle in 1999–2012.

References

    1. Centers for Disease, C. & Prevention. CDC Grand Rounds: the million hearts initiative. MMWR Morb Mortal Wkly Rep 61, 1017–1021 (2012).
    1. Wilson P. W. Diabetes mellitus and coronary heart disease. Am J Kidney Dis 32, S89–100 (1998).
    1. Keil U. et al. Classical risk factors and their impact on incident non-fatal and fatal myocardial infarction and all-cause mortality in southern Germany. Results from the MONICA Augsburg cohort study 1984–1992. Monitoring Trends and Determinants in Cardiovascular Diseases. Eur Heart J 19, 1197–1207 (1998).
    1. Smith S. C. Jr. Screening for high-risk cardiovascular disease: a challenge for the guidelines: comment on “systematic review of guidelines on cardiovascular risk assessment: which recommendations should clinicians follow for a cardiovascular health check?” Arch Intern Med 170, 40–42 (2010).
    1. Verschuren W. M. et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. Jama 274, 131–136 (1995).
    1. Sacco R. L. et al. American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Risk factors . Stroke 28, 1507–1517 (1997).
    1. Wilson P. W. et al. Prediction of coronary heart disease using risk factor categories. Circulation 97, 1837–1847 (1998).
    1. Kearney P. M. et al. Global burden of hypertension: analysis of worldwide data. Lancet 365, 217–223 (2005).
    1. Seaquist E. R. Addressing the burden of diabetes. Jama 311, 2267–2268 (2014).
    1. Reddy K. Global perspective on cardiovascular disease. In: Evidence-Based Cardiology. Yusuf S., Cairns J. A., Camm, A. J., Fallen E. L., Gersh B. J. (Eds). Wiley-Blackwell, London, UK (2009).
    1. Selvin E., Parrinello C. M., Sacks D. B. & Coresh J. Trends in prevalence and control of diabetes in the United States, 1988–1994 and 1999–2010. Ann Intern Med 160, 517–525 (2014).
    1. An R. Prevalence and Trends of Adult Obesity in the US, 1999–2012. ISRN Obes 2014, 185132 (2014).
    1. Wolf-Maier K. et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. Jama 289, 2363–2369 (2003).
    1. Hajjar I. & Kotchen T. A. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. Jama 290, 199–206 (2003).
    1. Guo F., He D., Zhang W. & Walton R. G. Trends in prevalence, awareness, management, and control of hypertension among United States adults, 1999 to 2010. J Am Coll Cardiol 60, 599–606 (2012).
    1. Carroll M. D. et al. Trends in serum lipids and lipoproteins of adults, 1960–2002. Jama 294, 1773–1781 (2005).
    1. Toth P. P., Potter D. & Ming E. E. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003–2006. J Clin Lipidol 6, 325–330 (2012).
    1. Ford E. S., Li C., Pearson W. S., Zhao G. & Mokdad A. H. Trends in hypercholesterolemia, treatment and control among United States adults. Int J Cardiol 140, 226–235 (2010).
    1. Jamerson K. et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359, 2417–2428 (2008).
    1. Brenner B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345, 861–869 (2001).
    1. Ward B. W. & Schiller J. S. Prevalence of multiple chronic conditions among US adults: estimates from the National Health Interview Survey, 2010. Prev Chronic Dis 10, E65 (2013).
    1. Kannel W. B. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 13, 3s–10s (2000).
    1. Wilson P. W., Kannel W. B., Silbershatz H. & D’Agostino R. B. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 159, 1104–1109 (1999).
    1. Onat A. et al. Dyslipidemic hypertension: distinctive features and cardiovascular risk in a prospective population-based study. Am J Hypertens 18, 409–416 (2005).
    1. Grundy S. M., Pasternak R., Greenland P., Smith S. Jr. & Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 100, 1481–1492 (1999).
    1. Neaton J. D. & Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 152, 56–64 (1992).
    1. Ji L. et al. Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients. Am J Med 126, 925.e911–922 (2013).
    1. Gaede P., Lund-Andersen H., Parving H. H. & Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358, 580–591 (2008).
    1. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. Bmj 317, 720–726 (1998).
    1. Grant R. W. & Kirkman M. S. Trends in the evidence level for the American Diabetes Association’s “Standards of Medical Care in Diabetes” from 2005 to 2014. Diabetes Care 38, 6–8 (2015).
    1. Standards of medical care in diabetes–2015: summary of revisions. Diabetes Care 38 Suppl, S4 (2015).
    1. Stone N. J. et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63, 2889–2934 (2014).
    1. Ganda O. P. Deciphering cholesterol treatment guidelines: a clinician’s perspective. Jama 313, 1009–1010 (2015).
    1. Estoppey D., Paccaud F., Vollenweider P. & Marques-Vidal P. Trends in self-reported prevalence and management of hypertension, hypercholesterolemia and diabetes in Swiss adults, 1997–2007. BMC Public Health 11, 114 (2011).
    1. MacDonald T. M. & Morant S. V. Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom. Br J Clin Pharmacol 65, 775–786 (2008).
    1. Wong N. D., Lopez V., Tang S. & Williams G. R. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol 98, 204–208 (2006).
    1. Centers for Disease Control and Prevention. National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 1999–2010. Available at (2012).
    1. Survey Questionnaires, Examination Components and Laboratory Components 2009–2010. .
    1. Centers for Disease Control and Prevention. National Center for Health Statistics. National Health and Nutrition Examination Survey Response Rates and CPS Totals, 2009–2010. A available at (2012).
    1. Johnson C. L. et al. National health and nutrition examination survey: analytic guidelines, 1999–2010. Vital Health Stat 2, 1–24 (2013).
    1. National Center for Health Statistics. National Health and Nutrition Examination Survey: Analytic Guidelines, 1999–2010. Available at (2013).
    1. Analytic Note Regarding 2007–2010 Survey Design Changes and Combining Data Across Other Survey Cycles. Available at: .
    1. James P. A. et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). Jama 311, 507–520 (2014).

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅